What does US 7,459,151 claim for phosphate removal, and how broad is the protection?

United States Drug Patent 7,459,151 claims oral phosphate removal using a crosslinked, water-insoluble polyallylamine copolymer with defined polymer structure and defined crosslinker and counterion parameters. The enforceable core is a method-of-treatment scope, not a composition claim framed as a drug product for a particular dosage form.

Independent claim coverage (claims 1 and 11)

Claim 1 and claim 11 are the primary method claims. Both require:

A method for removing phosphate (claim 1) or decreasing serum phosphate level (claim 11)
Oral administration to a patient “in need thereof”
A therapeutically effective amount of a pharmaceutical composition comprising a
Crosslinked, water insoluble polyallylamine copolymer
The copolymer “consists of”:
- a crosslinking agent, and
- repeat units represented by a defined structural formula (not fully reproduced in the text you provided), with
- n = an integer
- X− = a negatively charged counterion

From an infringement standpoint, the “consists of” language matters because it can narrow the composition/material set to only those elements within the claimed copolymer system (even though the pharmaceutical composition can still include “one or more carriers” under dependent claims).

Practical breadth consequence: any oral phosphate-removal product that uses a crosslinked, water-insoluble polyallylamine-based polymer matching the structural repeat unit concept, and that has a defined counterion X−, is within the claim geometry even if the rest of the formulation differs (carriers, etc.).

How do dependent claims narrow the scope (crosslinker, loading, counterion, carriers)?

Crosslinker limitation (claims 2, 12)

Claim 2: polymer is crosslinked with epichlorohydrin
Claim 12: same for the serum phosphate decrease method

This is a meaningful narrowing layer. Epichlorohydrin-crosslinked embodiments fall inside these dependent claims; epichlorohydrin-free embodiments would not.

Crosslinker amount (claims 3-4, 13-14)

Claim 3: crosslinking agent is about 2% to about 20% by weight of polymer (for claim 1)
Claim 4: same range with epichlorohydrin (for claim 2)
Claim 13: same range for claim 11
Claim 14: same range with epichlorohydrin for claim 12

These ranges create a quantitative “design-around” handle for competing polymer manufacturing routes: crosslink density outside that band can fall outside these dependent claims, while still potentially meeting the independent claims if the broader independent claim does not require the same quantitative band (it does not explicitly, based on your claim text).

Carrier inclusion (claims 5-7, 15-17)

Claims 5-7: pharmaceutical composition further comprises one or more carriers (claims tied to 1)
Claims 15-17: same concept for claims tied to 11

This does not restrict technology; it instead confirms formulation flexibility. A generic or reformulated product typically includes excipients/carriers anyway, so these dependent claims reduce the likelihood that defendants defeat the claims by pointing to excipient inclusion.

Counterion limitation (claims 8-10, 18-20)

Claim 8: X− represents chloride (dependent on claim 1)
Claim 9: chloride (dependent on claim 4)
Claim 10: chloride (dependent on claim 6)
Claim 18: chloride (dependent on claim 11)
Claim 19: chloride (dependent on claim 14)
Claim 20: chloride (dependent on claim 16)

This is a major claim-narrowing factor. If a product uses the same polymer architecture but a different counterion (for example, another anion form), the dependent claims might be avoided while the independent claims could still be implicated depending on whether X− is fixed or can vary under the independent claim’s structural definition.

Key point: dependent counterion limitations provide narrower “bolt-on” claim coverage; counterion selection can be a non-trivial formulation lever.

Claim scope mapping: what is “in,” what is “out,” and where design-arounds are most visible

In-scope elements (minimum requirements tied to claims 1/11)

A product is positioned to read on the independent method claims if it does all of the following:

Oral administration of a phosphate binding therapy
Uses a therapeutically effective amount of a pharmaceutical composition
The active includes a crosslinked, water-insoluble polyallylamine copolymer
The polymer “consists of” a crosslinking agent and defined repeat units with:
- n integer
- X− negative counterion

Potential out-of-scope triggers

Based on your provided claim language, the most visible out-of-scope triggers are:

Not water-insoluble polymer material (if engineered to be soluble or partially soluble)
Not crosslinked polymer
Polymer not meeting the polyallylamine copolymer definition (even if it is another polycation or another type of resin)
Counterion X− not matching the claimed structural definition (depending on how broadly the independent claim permits X−)
For dependent coverage, additional narrowing triggers:
- Crosslinker not epichlorohydrin
- Crosslinker loading outside 2% to 20% by weight
- X− not chloride (to avoid those dependent claims)

Patent landscape analysis: where US 7,459,151 sits in the “oral phosphate binder” competitive field

What this patent type covers

US 7,459,151 is a method-of-treatment patent directed to oral phosphate removal using a defined polyallylamine resin system. This matters because the competitive landscape for phosphate binders frequently includes:

polymeric binders,
calcium or iron salts,
and newer agents in different pharmacologic classes.

Enforceability focus: infringement analysis will typically hinge on whether a competitor’s product uses a water-insoluble, crosslinked polyallylamine copolymer meeting the structural and counterion constraints, and whether it is administered orally to reduce serum phosphate.

Where overlap typically occurs

Overlap is most likely with products that are:

polymer-based,
use amine-rich resins,
are chemically crosslinked,
and are formulated to be water-insoluble to bind phosphate in the GI tract.

Even when competitors market as “phosphate binders,” their protection risk usually correlates more with the polymer chemistry than the clinical endpoints.

Key competitive “adjacency” categories (risk orientation)

Without bringing in additional external case-specific prosecution history, the most useful landscape segmentation for this particular claim set is:

Direct chemistry similarity: crosslinked polyallylamine resins with similar counterion forms
- Highest collision with claim 1/11 independent scope.
Crosslinker variant products: same polymer backbone but different crosslinker chemistry
- Likely to avoid dependent epichlorohydrin claims (2/12, 4/14), but may still risk the independent claims if the epichlorohydrin limitation is not required there.
Counterion-form variant products: same resin but counterion changed
- Likely avoids dependent “chloride” claims (8-10, 18-20) while still potentially risking independent claim scope depending on how X− is treated in practice.
Non-polyallylamine phosphate binders (different polymer families or inorganic salts)
- Lower collision with the claimed resin architecture.

What does the claim structure imply for freedom-to-operate (FTO)?

1) Independent claims force chemistry-level matching

Because claims 1 and 11 independently require:

crosslinked,
water-insoluble polyallylamine copolymer,
with defined repeat units and X−,

an FTO assessment cannot stop at “phosphate binder” categorization. It must map to polymer material science and the counterion form.

2) Dependent claims create multiple “layers” of value

Dependent claims add orthogonal constraints that help the patent owner in two ways:

Fallback positions for enforcement: if a competitor avoids one parameter (for example epichlorohydrin), the patentee can assert other narrower parameters if still met (for example within 2%-20% or chloride counterion).
More precise invalidation attacks for challengers, because each dependent layer is separately testable against manufacturing specifications.

3) Counterion and crosslink loading are the most actionable design parameters

Among the claim add-ons you provided, the most operationally manipulable are:

X− counterion identity (chloride vs other anions)
crosslinker identity (epichlorohydrin vs other agents)
crosslinker loading (2%-20% by weight band)

These parameters often have direct formulation/manufacturing controls, making them the most likely levers in competitive product development.

Claim-by-claim compression table (scope and narrowing points)

Claim	Method endpoint	Oral route	Polymer constraints	Crosslinker	Crosslinker % (by weight)	Counterion	Extra formulation
1	removing phosphate	Yes	crosslinked, water-insoluble polyallylamine copolymer with defined repeat units; n integer; X− counterion	Not specified in claim 1	Not specified	X− (defined structurally)	Requires pharmaceutical composition
2	(depends on 1)	Yes	Same as claim 1	Epichlorohydrin	Not specified	X−	Pharmaceutical composition
3	(depends on 1)	Yes	Same as claim 1	Not specified	2% to 20%	X−	Pharmaceutical composition
4	(depends on 2)	Yes	Same as claim 2	Epichlorohydrin	2% to 20%	X−	Pharmaceutical composition
5	(depends on 4)	Yes	Same as claim 4	Same	Same	X−	One or more carriers
6	(depends on 1)	Yes	Same as claim 1	Same as claim 1	Same as claim 1	Chloride in claim 8 only (this claim is not limited here unless tied)	Requires carriers (by dependency)
7	(depends on 4)	Yes	Same as claim 4	Same	Same	X−	One or more carriers
8	(depends on 1)	Yes	Same as claim 1	Same	Same	Chloride	Requires carriers (via the dependency chain shown in your text)
9	(depends on 4)	Yes	Same as claim 4	Epichlorohydrin	2% to 20%	Chloride	Carriers via dependency chain
10	(depends on 6)	Yes	Same as claim 6	Crosslinker per 6 dependency	As applicable	Chloride	Carriers via dependency chain
11	decreasing serum phosphate	Yes	Same polymer constraints as claim 1	Not specified	Not specified	X−	Pharmaceutical composition
12	(depends on 11)	Yes	Same as claim 11	Epichlorohydrin	Not specified	X−	Pharmaceutical composition
13	(depends on 11)	Yes	Same as claim 11	Not specified	2% to 20%	X−	Pharmaceutical composition
14	(depends on 12)	Yes	Same as claim 12	Epichlorohydrin	2% to 20%	X−	Pharmaceutical composition
15	(depends on 14)	Yes	Same as claim 14	Epichlorohydrin	2% to 20%	X−	One or more carriers
16	(depends on 12)	Yes	Same as claim 12	Epichlorohydrin	Not specified	X−	One or more carriers
17	(depends on 14)	Yes	Same as claim 14	Epichlorohydrin	2%-20%	X−	One or more carriers
18	(depends on 11)	Yes	Same as claim 11	Not specified	Not specified	Chloride	Carriers via dependency chain
19	(depends on 14)	Yes	Same as claim 14	Epichlorohydrin	2% to 20%	Chloride	Carriers via dependency chain
20	(depends on 16)	Yes	Same as claim 16	Epichlorohydrin	Not specified	Chloride	Carriers via dependency chain

Note: Your excerpt does not include the full polymer structural formula text; it therefore cannot be reconstructed with chemical precision here. The table reflects only the limitations present in your claim text.

How to interpret the “scope of claims” strategically

1) The patent is built around a resin architecture, not a single brand formulation

Because the claim describes the active polymer with structural constraints and then allows pharmaceutical compositions with carriers, the patent is designed to remain relevant even if formulations change.

2) It supports both independent assertion and dependency fallback

Independent method coverage (1 and 11) captures broad resin categories. Dependent claims narrow to epichlorohydrin crosslinking, specific loading, and chloride counterions. In enforcement, that can matter if a competitor argues only one chemical parameter differs.

3) The oral route anchors to GI exposure

If a competitor delivers the binder via non-oral route (or as part of a different administration paradigm), it can fall outside method scope even if the resin chemistry matches.

Key Takeaways

US 7,459,151 protects oral phosphate removal methods using a crosslinked, water-insoluble polyallylamine copolymer with defined repeat-unit structure and counterion X− (independent claims 1 and 11).
The strongest narrowing layers are: epichlorohydrin crosslinker (claims 2 and 12), crosslinker loading 2% to 20% by weight (claims 3-4 and 13-14), and chloride counterion (claims 8-10 and 18-20).
The patent’s formulation scope is flexible because it allows “one or more carriers” (claims 5-7 and 15-17).
The most actionable competitive design-arounds from a claims perspective are counterion form, crosslinker identity, and crosslinker loading, while the broad independent claims still require the polyallylamine resin architecture and oral administration.

FAQs

1) Does US 7,459,151 claim a specific dosage form (tablet, powder, etc.)?

No. It claims a pharmaceutical composition for oral administration and allows one or more carriers, without specifying dosage form.

2) What is the core chemical limitation that drives infringement risk?

A crosslinked, water-insoluble polyallylamine copolymer with defined repeat units (n integer) and a negatively charged counterion X−, as used in an oral phosphate-removal method.

3) Can a product avoid the patent by changing the crosslinker?

It can potentially avoid dependent claims that require epichlorohydrin (claims 2/12 and 4/14), but the independent claims can still be implicated unless the different crosslinker causes the polymer to fail the independent “crosslinked polyallylamine copolymer” structural definition.

4) Is chloride a required limitation for all claims?

No. Chloride is required only in the dependent claims: 8-10 and 18-20.

5) Is the clinical endpoint tied to “serum phosphate decrease” only in one claim set?

No. The claims split the endpoint framing into removing phosphate (claim 1) and decreasing serum phosphate level (claim 11), but both use the same oral polymer resin architecture.

References (APA)

[1] United States Patent No. 7,459,151.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0716606	⤷ Start Trial	CA 2002 00003	Denmark	⤷ Start Trial
European Patent Office	0716606	⤷ Start Trial	SPC/GB02/011 200210	United Kingdom	⤷ Start Trial
European Patent Office	0716606	⤷ Start Trial	SPC004/2002	Ireland	⤷ Start Trial
European Patent Office	0716606	⤷ Start Trial	C00716606/01	Switzerland	⤷ Start Trial
European Patent Office	0716606	⤷ Start Trial	CA 2009 00048	Denmark	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,459,151

Summary for Patent: 7,459,151